[Virus factors determining the outcome of IFN treatment for chronic hepatitis C].
Kanazawa
Nobuhiko
N
Department of Gastroenterology and Hepatology, School of Medicine, Tokyo Medical and Dental University.
Nakagawa
Mina
M
Watanabe
Hideki
H
Sakamoto
Naoya
N
Enomoto
Nobuyuki
N
D000998:Antiviral Agents / Q000627:therapeutic use*; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D009154:Mutation; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome; D014759:Viral Envelope Proteins / Q000235:genetics; D017361:Viral Nonstructural Proteins / Q000235:genetics; D014764:Viral Proteins / Q000235:genetics; D012324:RNA-Dependent RNA Polymerase
D000998:Antiviral Agents; D007372:Interferons; D012254:Ribavirin; D014759:Viral Envelope Proteins; D017361:Viral Nonstructural Proteins; D014764:Viral Proteins; C400562:HVR1 protein, Hepatitis C virus; C091015:glycoprotein E2, Hepatitis C virus; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase